Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a phone app boost Pill-Taking for high blood pressure?

NCT ID NCT04708756

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a mobile app called Collabree could help people with high blood pressure take their medication more regularly. 181 adults in Switzerland who took at least 4 blood pressure pills daily participated. They were randomly assigned to use the app or receive standard care, and their medication taking was tracked for 90 days. The goal was to see if the app improved adherence and lowered blood pressure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Collabree mobile phone application
What this could lead to
If it works, this could offer a simple, app-based way to help people with high blood pressure stick to their medication routine and improve blood pressure control.
What could go wrong
This is a small, completed study with 181 participants, so results may not apply to everyone. The app's effectiveness depends on consistent smartphone use, and it does not replace standard medical care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

181 people

The number who actually took part.

Started

Jul 2021

Finished

Feb 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Informed consent as documented by signature 2. Over 18 years of age at date of randomization 3. Primary or secondary arterial hypertension 4. Patient in an outpatient clinical setting 5. Prescribed a therapy consisting of 4 or more tablets taken per day 6. Stable medication regime that patient has been taking for at least 4 weeks 7. Participant administers their own medications 8. Participant owns a smartphone with a data plan or constant internet access during the study visits and at home to use the application 9. Minimal required smartphone operating system is iOS 12 and Android 8 (Oreo) 10. Adequate communication in German or Swiss-German (all study documentation will only be set to the German language). Exclusion Criteria: 1. Cognitive impairment that limits ability to understand and complete questionnaires 2. Ongoing evaluation for secondary forms of hypertension 3. 3\. Changes in the participant's medication treatment plan after the baseline visit during the intervention period, unless due to a diagnosis of symptomatic hypotension (in-clinic blood pressure below 110/60 mmHg and symptoms of orthostasis or dizziness) or stage 2 hypertension (in-clinic blood pressure \> 160/100 mmHg); after the endpoint (day 90) visit, a change in the treatment plan will be permitted 4. Uncontrolled hypertension (in-clinic blood pressure \> 180/110 mmHg) 5. Inability to operate a mobile phone and the Collabree application 6. Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. 7. Pregnancy or intention to become pregnant in next 6 months 8. Enrollment of the Sponsor or Investigator, their family members, employees and other dependent persons 9. Participation in another clinical trial 10. Physician-estimated life expectancy of less than 6 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertensive disorder Medication Adherence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University Hospital Basel

    Basel, Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.